In fact, we observe that the signaling of oncogenic kinases along the Ras/ERK and PI3K/AKT pathways is not independent of tumor immunity in HNSCC, suggesting that targeting some of these components may be a viable option to suppress tumor growth or to reactivate immune responses. The gene discussed is PIK3CD; the disease is neoplasm.